Insurers Should Incentivize Non-Drug Treatments for Chronic Pain
An LDI Fellow and Chronic Pain Researcher Call on Health Plans To Lower Barriers to Physical Therapy, Acupuncture, and Interdisciplinary Pain Care
In Their Own Words
The following excerpt is from an op-ed that first appeared in The Hill on May 9th, 2024.
To appreciate one of the great snafus of American health care, consider the plight of people who are poor, elderly — often with a disability — and insured by both Medicare and Medicaid.
One might think having two insurers must be better than one. But these two programs were never meant to work together. Rather than cooperating, the programs follow rules that create incentives for each partner to shift costs to the other, while patients are stuck in the middle, without the care they need.
For dually eligible Americans, bureaucratic nightmares are their daily realities.
These accounts are emblematic of the problems that plague the nearly 13 million dually eligible individuals with disabilities or are old enough to qualify for Medicare and poor enough to get Medicaid. Nearly all make less than $20,000 a year. They are arguably sicker than any other group enrolled in Medicare or Medicaid, with lifespans that are a decade shorter than other patients. And they cost the government a cool half a trillion dollars a year — a sum greater than any other group and one that will surely rise as the country ages.
Read the entire op-ed here.

An LDI Fellow and Chronic Pain Researcher Call on Health Plans To Lower Barriers to Physical Therapy, Acupuncture, and Interdisciplinary Pain Care
Chart of the Day: Researchers Urge Easier Renewals and Better Support To Prevent Gaps in Care
While They Wait for Medicare, People Approved for Social Security Disability Die at Higher Rates Compared to the General Public
Two Pediatricians Share Key Dates and Practical Next Steps
Medicare’s Payment Plan Can Ease Seniors’ Crushing Drug Costs but Medicare Buries it in the Fine Print
Even With Lower Prices, Medicare, Medicaid, and Other Insurers Tighten Coverage for Drugs Like Mounjaro and Zepbound Using Prior Authorization and Other Tools